Innate Pharma Profit Margin

The latest profit margin for IPHA is -6.93% as of December 2025. That compares with -35.75% in the prior-year period — down 1838.7% year over year. That is below the Healthcare sector average of 15.52%. Investors often review this figure alongside Innate Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, IPHA's profit margin moved from -35.75% to -6.93% — a 1838.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Innate Pharma's valuation or profitability profile.

Against Healthcare companies, IPHA currently prints -6.93% for profit margin, while the sector average sits near 15.52%. That is roughly 4565.9% below the sector mean. Large gaps often invite a closer look at Innate Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Innate Pharma converts resources into returns. At -6.93%, IPHA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -35.75% in the prior-year period — down 1838.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IPHA's profit margin (-6.93%), review year-over-year change from -35.75%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.